Key result
This report summarizes the experience of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma, without detailing specific outcomes.
Observational (n=13)
No
This report summarizes a single-center experience of lung resection combined with adjuvant therapy for patients with metastatic osteogenic sarcoma.
Answers are grounded in this paper and cite their sources.
Does not provide outcome data to inform lung resection plus adjuvant therapy in metastatic osteogenic sarcoma; leaves open its clinical role.
Osteogenic sarcoma, excluding the paraosteal osteosarcoma, has a grave prognosis, half of the patients dying within 1 year following ablative surgery of the primary lesion. Once pulmonary metastasis is detected, most patients do not survive more than 3 years. Various attempts by investigators to prolong patient survival, including surgery, chemotherapy, immunotherapy, radiation therapy, and combined modalities, have met with some success. This report is a summary of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma in our intstitute in the past 7 years.
No takes yet. Share an insight, caveat, or question.
Huang et al. (1978) conducted an observational in Metastatic osteogenic sarcoma (n=13). Lung resection and adjuvant chemo- and/or immunotherapy was evaluated. This report summarizes the experience of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma, without detailing specific outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: